Laurus Labs Full Year 2024 Earnings: EPS Misses Expectations

Laurus Labs (NSE:LAURUSLABS) Full Year 2024 Results

Key Financial Results

• Revenue: ₹50.7b (down 16% from FY 2023).
• Net income: ₹1.61b (down 80% from FY 2023).
• Profit margin: 3.2% (down from 13% in FY 2023). The decrease in margin was driven by lower revenue.
• EPS: ₹2.98 (down from ₹14.69 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Laurus Labs EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are up 2.5% from a week ago.

Risk Analysis

It is worth noting though that we have found 3 warning signs for Laurus Labs (1 is significant!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.